Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Aurion Biotech completes enrollment in phase 3 ASTRA study of AURN001 for corneal ...

25 September 2026 · By · Wire by Fusion42

Published

25 September 2026

Topic

operational-macro

◆ Sectors

BiotechMedtechDiagnostics

◆ Geography

United States

◆ Source

Read at ophthalmologytimes.com →

◆ Verified

Fusion42 · 25 September 2026 · Fusion42 review

Aurion Biotech has completed enrollment for the phase 3 ASTRA clinical trial evaluating AURN001 for treating corneal edema due to corneal endothelial dysfunction.

This Wire brief sits within Fusion42's coverage of Biotech, Medtech and Diagnostics, and 2 sources have reported it between 23 Sep 2026 and 25 Sep 2026.

◆ ◆ The Wire takeaway

You have a new clinical endpoint to benchmark if developing treatments for corneal edema. Aurion's phase 3 completion signals clear regulatory and commercial validation in ophthalmic biotech.

◆ Coverage

2 sources · first reported 23 Sep 2026 · latest 25 Sep 2026

◆ Related on Wire

◆ Topics

BiotechMedtechDiagnosticsclinical-trialcorneal-edemaeye-diseasephase-3biotech